PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Phillips et al.)
Serial No. 09/735,363) Art Unit: 1635
Filed: December 12, 2000	Examiner: Jane Zara
For: THERAPEUTICALLY USEFUL SYNTHETIC OLIGONUCLEOTIDES)

REQUEST FOR CONTINUED EXAMINATION AND RESPONSE TO FINAL OFFICE ACTION

Mailstop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants file this Request for Continued Examination (RCE) pursuant to 37 C.F.R. § 1.114. A Petition for Extension of Time under 37 C.F.R. § 1.136 for a one-month extension of time to file a Response to the Final Office Action mailed on June 3, 2003, a four-month period of Response to which expires on October 3, 2003, is enclosed together with the authorization to charge Deposit Account No. 11-0855 in the amount of \$55.00 pursuant to 37 C.F.R. §1.17(a)(3) and to charge \$385.00 to cover the payment of fees for the RCE pursuant to 37 C.F.R. § 1.17(e)

I hereby certify that this correspondence is being transmitted to the U.S. Parent and Trademark Office via facsimile number 703.872.9306 attention Examiner Jane Zara on October 1, 2003:

Elena S. Polovnikova, Ph.D.- Reg. No. 52,130

ATLLIB02 140325.3

Applicant: Phillips et al.
Application Serial No. 09/735,363
Request for Continued Examination and Response to Final Office Action
Page 2 of 12

On June 3, 2003, a Final Office Action was mailed in the above-referenced application. On Monday, August 4, 2003, Applicants filed a Response to the Final Office Action. On August 29, 2003, the Examiner issued an Advisory Action maintaining the rejection of the Final Office Action. In response to the Advisory Action mailed August 29, 2003, Applicants respectfully request entry of the following amendments and reconsideration of the rejected claims based upon the following amendments and remarks.

No additional fees are believed due, however, the Commissioner is hereby authorized to charge any additional filing fee and credit any refund to Deposit Account No. 11-0855.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks begin on page 7 of this paper.